Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".

Autor: Harms MH; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands., van Buuren HR; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Meer AJ; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: a.vandermeer@erasmusmc.nl.
Jazyk: angličtina
Zdroj: Journal of hepatology [J Hepatol] 2020 Jun; Vol. 72 (6), pp. 1211-1212. Date of Electronic Publication: 2020 Mar 26.
DOI: 10.1016/j.jhep.2020.02.012
Abstrakt: Competing Interests: Conflict of interest MHH reports a speaker’s free from Zambon Nederland, and thesis printing costs expenses from Zambon Nederland, Intercept Pharma Benelux, Dr Falk Pharma, Astellas Pharma, Tramedico, Sysmex and Pentax. HvB was a consultant for Intercept Pharma Benelux and received unrestricted research grants from Intercept Pharmaceuticals and from Zambon Nederland. AJvdM reports speaker’s fees from MSD, Gilead Sciences, AbbVie Pharmaceuticals and Zambon Nederland, received an unrestricted grant from Gilead Sciences, and reports travel expenses covered by Dr Falk Pharma. Please refer to the accompanying ICMJE disclosure forms for further details.
Databáze: MEDLINE